A modified physiological BCS for prediction of intestinal absorption in drug discovery

Molecular Pharmaceutics

Volumn 7, Issue 5, 2010, Pages 1478-1487

  Zaki, Noha M ^a,b   Artursson, Per ^a   Bergström, Christel A S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Ain Shams University   (Egypt)

Author keywords

BCS; biorelevant dissolution medium; fasted state; fed state; intestinal absorption; intestinal fluid; permeability; Solubility

Indexed keywords

ACARBOSE; AMILORIDE; AMITRIPTYLINE; CARBAMAZEPINE; CARBON 14; CYCLOSPORIN A; DIAZEPAM; DIGOXIN; DIPYRIDAMOLE; ENALAPRIL; ERYTHROMYCIN; FELODIPINE; FLUOROURACIL; FUROSEMIDE; KETOCONAZOLE; LOPERAMIDE; MANNITOL; METHYLDOPA; METOCLOPRAMIDE; PHOSPHATE; PRAVASTATIN; SCOPOLAMINE; SPIRONOLACTONE; TRANEXAMIC ACID; TRITIUM; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL LINE; CLASSIFICATION; DIET RESTRICTION; DRUG ABSORPTION; DRUG DIFFUSION; DRUG SOLUBILITY; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE ABSORPTION; INTESTINE FLUID; INTESTINE MUCOSA PERMEABILITY; IONIC STRENGTH; MASS SPECTROMETRY; MOLECULE; MONOLAYER CULTURE; NONHUMAN; PH; PREDICTION; PRIORITY JOURNAL; RAT; SOLID STATE; ULTRAVIOLET SPECTROPHOTOMETRY;

ADMINISTRATION, ORAL; BIOPHARMACEUTICS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; FASTING; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACOKINETICS; SOLUBILITY;

EID: 77957738213     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100124f     Document Type: Article

References (44)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeny, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
2. Morphy, R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds J. Med. Chem. 2006, 49 (10) 2969-2978
3. Alsenz, J.; Kansy, M. High throughput solubility measurement in drug discovery and development Adv. Drug Delivery Rev. 2007, 59 (7) 546-567
4. Bergström, C. A. S.; Wassvik, C. M.; Johansson, K.; Hubatsch, I. Poorly soluble marketed drugs display solvation limited solubility J. Med. Chem. 2007, 50 (23) 5858-5862
5. Tsinman, K.; Avdeef, A.; Tsinman, O.; Voloboy, D. Powder dissolution method for estimating rotating disk intrinsic dissolution rates of low solubility drugs Pharm. Res. 2009, 26 (9) 2093-2100
6. Kesisoglou, F.; Panmai, S.; Wu, Y. Nanosizing - oral formulation development and biopharmaceutical evaluation Adv. Drug Delivery Rev. 2007, 59 (7) 631-44
7. Porter, C. J.; Trevaskis, N. L.; Charman, W. N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 2007, 6 (3) 231-248
8. Shan, N.; Zaworotko, M. J. The role of cocrystals in pharmaceutical science Drug Discovery Today 2008, 13 (9-10) 440-446
9. Galia, E.; Nicolaides, E.; Horter, D.; Lobenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 1998, 15 (5) 698-705
10. Lue, B. M.; Nielsen, F. S.; Magnussen, T.; Schou, H. M.; Kristensen, K.; Jacobsen, L. O.; Mullertz, A. Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound Eur. J. Pharm. Biopharm. 2008, 69 (2) 648-657
11. Persson, E. M.; Gustafsson, A. S.; Carlsson, A. S.; Nilsson, R. G.; Knutson, L.; Forsell, P.; Hanisch, G.; Lennernas, H.; Abrahamsson, B. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids Pharm. Res. 2005, 22 (12) 2141-2151
12. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Res. Commun. 1991, 175 (3) 880-885
13. Tavelin, S.; Milovic, V.; Ocklind, G.; Olsson, S.; Artursson, P. A conditionally immortilized epithelial cell line for studies of intestinal drug transport J. Pharmacol. Exp. Ther. 1999, 290 (3) 1212-1221
14. Johnson, K. C.; Swindell, A. C. Guidance in the setting of drug particle size specifications to minimize variability in absorption Pharm. Res. 1996, 13 (12) 1795-1798
15. Willmann, S.; Schmitt, W.; Keldenich, J.; Lippert, J.; Dressman, J. B. A physiological model for the estimation of the fraction dose absorbed in humans J. Med. Chem. 2004, 47 (16) 4022-4031
16. Avdeef, A.; Kansy, M.; Bendels, S.; Tsinman, K. Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis Eur. J. Pharm. Sci. 2008, 33 (1) 29-41
17. Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution an in vivo bioavailability Pharm. Res. 1995, 12 (3) 413-420
18. FDA, Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. For further information: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070246.pdf (accessed June 30, 2010).
19. Mithani, S. D.; Bakatselou, V.; TenHoor, C. N.; Dressman, J. B. Estimation of the increase in solubility of drugs as a function of bile salt concentration Pharm. Res. 1996, 13 (1) 163-167
20. Dressman, J. B.; Reppas, C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci. 2000, 11 (Suppl 2) S73-80
21. Dressman, J. B.; Vertzoni, M.; Goumas, K.; Reppas, C. Estimating drug solubility in the gastrointestinal tract Adv. Drug. Delivery Rev. 2007, 59 (7) 591-602
22. Tavelin, S.; Taipalensuu, J.; Soderberg, L.; Morrison, R.; Chong, S.; Artursson, P. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers Pharm. Res. 2003, 20 (3) 397-405
23. Linnankoski, J.; Makela, J.; Palmgren, J.; Mauriala, T.; Vedin, C.; Ungell, A. L.; Lazorova, L.; Artursson, P.; Urtti, A.; Yliperttula, M. Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models J. Pharm. Sci. 2010, 99 (4) 2166-2175
24. Matsson, P.; Bergstrom, C. A.; Nagahara, N.; Tavelin, S.; Norinder, U.; Artursson, P. Exploring the role of different drug transport routes in permeability screening J. Med. Chem. 2005, 48 (2) 604-613
25. Sweetman, S. C., Ed. Martindale: The complete drug reference [online]; Pharmaceutical Press: London; www.medicinescomplete.com (accessed Jan 29, 2010).
26. FASS, the Swedish Physician Desk Reference; http://www.fass.se/LIF/home/ (accessed Jan 29, 2010).
27. Oh, D. M.; Curl, R. L.; Amidon, G. L. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model Pharm. Res. 1993, 10 (2) 264-270
28. Bergström, C. A. S.; Norinder, U.; Luthman, K.; Artursson, P. Experimental and computational screening models for prediction of aqueous drug solubility Pharm. Res. 2002, 19 (2) 182-188
29. Paul, E. C.; Hochman, J.; Quaroni, A. Conditionally immortalized intestinal epithelial cells: novel approach for study of differentiated enterocytes Am. J. Physiol. 1993, 265 (1 Pt 1) C266-278
30. Tavelin, S.; Taipalensuu, J.; Hallbook, F.; Vellonen, K. S.; Moore, V.; Artursson, P. An improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: characterization of transport routes Pharm. Res. 2003, 20 (3) 373-381
31. Tavelin, S.; Gråsjö, J.; Taipalensuu, J.; Ocklind, G.; Artursson, P. Applications of epithelial cell culture in studies of drug transport Methods Mol. Biol. 2002, 72, 188-233
32. FDA, Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. For further information: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070241.pdf (accessed June 30, 2010).
33. Lagerlof, H. O.; Johansson, C.; Ekelund, K. Studies of gastrointestinal interactions. VI. Intestinal flow, mean transit time, and mixing after composite meals in man Scand. J. Gastroenterol. 1974, 9 (3) 261-270
34. Read, N. W.; Cammack, J.; Edwards, C.; Holgate, A. M.; Cann, P. A.; Brown, C. Is the transit time of a meal through the small intestine related to the rate at which it leaves the stomach? Gut 1982, 23 (10) 824-828
35. Fagerberg, J.; Tsinman, O.; Sun, N.; Tsinman, K.; Avdeef, A.; Bergström, C. A. S. Dissolution Rate and Apparent Solubility of Poorly Soluble Compounds in Biorelevant Dissolution Media. Mol. Pharmaceutics 2010, published online May 27, http://dx.doi.org/10.1021/mp100049m.
36. Charman, W. N.; Porter, C. J.; Mithani, S.; Dressman, J. B. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH J. Pharm. Sci. 1997, 86 (3) 269-282
37. Lelawongs, P.; Barone, J. A.; Colaizzi, J. L.; Hsuan, A. T.; Mechlinski, W.; Legendre, R.; Guarnieri, J. Effect of food and gastric acidity on absorption of orally administered ketoconazole Clin. Pharm. 1988, 7 (3) 228-235
38. Russell, T. L.; Berardi, R. R.; Barnett, J. L.; O'Sullivan, T. L.; Wagner, J. G.; Dressman, J. B. pH-related changes in the absorption of dipyridamole in the elderly Pharm. Res. 1994, 11 (1) 136-143
39. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS.: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 2005, 22 (1) 11-23
40. Stella, V. J.; Nti-Addae, K. W. Prodrug strategies to overcome poor water solubility Adv. Drug Delivery Rev. 2007, 59 (7) 677-694
41. Wassvik, C. M.; Holmen, A. G.; Draheim, R.; Artursson, P.; Bergstrom, C. A. Molecular characteristics for solid-state limited solubility J. Med. Chem. 2008, 51 (10) 3035-3039
42. Jain, N.; Yalkowsky, S. H. Estimation of the aqueous solubility I: application to organic nonelectrolytes J. Pharm. Sci. 2001, 90 (2) 234-252 (Pubitemid 32158051)
43. Dollery, C. T., Ed. Therapeutic drugs, 2nd ed.; Churchill Livingstone: New York, 1999.
44. Zhao, Y. H.; Le, J.; Abraham, M. H.; Hersey, A.; Eddershaw, P. J.; Luscombe, C. N.; Butina, D.; Beck, G.; Sherborne, B.; Cooper, I.; Platts, J. A. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors J. Pharm. Sci. 2001, 90 (6) 749-784